Drug Profile

CZ 112

Alternative Names: 9-Nitrocamptothecin propionate; Rubitecan prodrug

Latest Information Update: 20 Apr 2011

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator The Stehlin Foundation for Cancer Research
Developer SuperGen
Class Antineoplastics; Camptothecins; Small molecules
Mechanism of Action DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer

Most Recent Events

13 Jul 2004 This compound is still in active development
17 Feb 2000 A preclinical study has been added to the pharmacodynamics section
05 Jan 1999 Phase-I clinical trials in Cancer in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com